Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.
The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.
The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.
The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.
Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。